Prospects of S1P Inhibitors for Treatment of Ulcerative Colitis: What Pharmacists Need to Know

Prospects of S1P Inhibitors for Treatment of Ulcerative Colitis: What Pharmacists Need to Know

On-Demand 2-hour Accredited Educational Activity

Faculty Presenter

Patrick Nichols, PharmD
Clinical Pharmacist
Vanderbilt University Medical Center
Nashville, Tennessee
 
Program Description
Ulcerative colitis (UC) is one of 2 conditions classified as inflammatory bowel disease. UC is more common than Crohn disease and primarily affects the rectum and distal colon. As UC is a chronic, lifelong disease with no cure, appropriate pharmacologic management is important to prevent unnecessary surgical intervention that can result in a colectomy. Current treatment consists mostly of injectable biologic therapies that are associated with multiple adverse reactions, but a new class of medications being investigated for use in UC is the sphingosine 1-phosphate (S1P) inhibitors. These agents have potential to fulfill an unmet need for an agent in the treatment of moderate to severe UC for patients resistant to other therapies. S1P inhibitors are oral pharmacologic agents currently approved for other indications to decrease proinflammatory processes. The S1P inhibitors may have potentially fewer adverse effects, although their future use in therapy may not be effective for all patients. This activity will review the importance of managing patient expectations and investigate the potential place of S1P inhibitors in the UC treatment paradigm.

Target audience: Retail pharmacists
Type of activity: Application
Release date: April 15, 2021
Expiration date: April 15, 2022
Time to complete activity: 2 hours
Fee: Free

Educational Objectives
At the completion of this activity, participants will be able to:

• Distinguish the epidemiology and clinical presentation of ulcerative colitis (UC) and differentiating factors of UC and Crohn disease
• Classify the role of sphingosine 1-phosphate (S1P) receptor modulators and the mechanism of action of this drug class in targeting UC
• Examine the clinical safety and efficacy data surrounding the emerging S1P receptor modulators in treating UC
• Employ evidence-based practice guidelines and clinical data surrounding new treatments into management of patients with UC

 Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 2 contact hours (0.20 CEU) under the ACPE universal activity number 0290-0000-21-150-H01-P. The activity is available for CE credit through April 15, 2022.


Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, read the article in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
 

---

Disclosures

Patrick Nichols, PharmD, has no relevant financial relationships with commercial interests to disclose.

Pharmacy Times Continuing Education™ Planning Staff – Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Michelle Carlson, PharmD, RPh; Kelly McCormick; Susan Pordon; and Brianna Winters have no relevant financial relationships with commercial interests to disclose.

An anonymous peer reviewer is used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms